Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute ...
Conversion of $450,000 of outstanding debt into shares strengthens the company's balance sheet and reduces overall debt burden. Lenders' decision to convert debt to equity at market price ...
This transaction strengthens the Company's balance sheet and reduces its debt burden ... in HCWC by converting a portion of their debt to equity at the current market price, without any discounts ...
TULIKIVI CORPORATION FINANCIAL STATEMENTS RELEASE 7 MARCH 2025 AT 1 PM - The Tulikivi Group’s net sales were EUR 8.4 million (EUR 9.9 million, 10–12/2023) in the fourth quarter and EUR 33.3 million ...
(Holdings) Inc. agrees to conversion of debt into equity, removing all existing debt from Dogwood’s balance sheet ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq ...
Largest shareholder, CK Life Sciences Int’l., (Holdings) Inc. agrees to conversion of debt into equity, removing all existing debt from Dogwood’s balance sheet We apologize, but this video has failed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results